Evaluation of Marijuana Compounds on Neuroimmune Endpoints in Experimental Autoimmune Encephalomyelitis. Issue 1 (21st February 2018)

• Record Type: Journal Article
• Authors: Kaplan, Barbara L. F.
• Editors: Costa, Lucio G; Davila, Julio C.; Lawrence, David A.; Reed, Donald J.
• Is Part Of: Current protocols in toxicology. Volume 75:Issue 1(2018)
• Page Start: 11.25.1
• Page End: 11.25.22
• Publication Date: 2018-02-21
• Subjects: autoimmune -- cannabinoids -- marijuana -- multiple sclerosis; Toxicology -- Laboratory manuals; Toxicology -- methods; Toxicology; Laboratory Manual; Electronic books; Laboratory manuals; 571.95028
• DOI: 10.1002/cptx.43
• Languages: English
• ISSNs: 1934-9254

Abstract

Abstract: Cannabinoid compounds refer to a group of more than 60 plant‐derived compounds in Cannabis sativa, more commonly known as marijuana. Exposure to marijuana and cannabinoid compounds has been increasing due to increased societal acceptance for both recreational and possible medical use. Cannabinoid compounds suppress immune function, and while this could compromise one's ability to fight infections, immune suppression is the desired effect for therapies for autoimmune diseases. It is critical, therefore, to understand the effects and mechanisms by which cannabinoid compounds alter immune function, especially immune responses induced in autoimmune disease. Therefore, this unit will describe induction and assessment of the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis (MS), and its potential alteration by cannabinoid compounds. The unit includes three approaches to induce EAE, two of which provide correlations to two forms of MS, and the third specifically addresses the role of autoreactive T cells in EAE. © 2018 by John Wiley & Sons, Inc.